Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01462383 · ClinicalTrials.gov registry record
The Role of the EKG in Anticancer Drug Development
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 525
- Enrollment target
NCT01462383: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT01462383 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 525 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01462383 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 525 participants
- Enrollment target
Study Summary
Primary Objective: -Evaluate incidence of cardiac complications in Phase I patients. Secondary Objective: -To identify variables (i.e. number of electrocardiograms (EKG) performed) that lead to the detection of cardiac events.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01462383
The ClinicalTrials.gov registry entry for NCT01462383 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 525 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01462383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01462383 about?
NCT01462383 is a clinical study titled "The Role of the EKG in Anticancer Drug Development". Primary Objective: -Evaluate incidence of cardiac complications in Phase I patients. Secondary Objective: -To identify variables (i.e. number of electrocardiograms (EKG) performed) that lead to the detection of cardiac events.
What is the current status of trial NCT01462383?
This trial is currently completed. The enrollment target is 525 participants. The study started on 2011-01. Estimated completion is 2011-11.
Who is sponsoring clinical trial NCT01462383?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.